RPS6KB2 (ribosomal protein S6 kinase B2) is a serine/threonine kinase that phosphorylates ribosomal protein S6 and acts downstream of mTOR signaling to promote cell proliferation, growth, and cell cycle progression 1. The gene operates in an alternative mTOR pathway regulated by MEAK7 and participates in positive regulation of translational initiation 1. RPS6KB2 is aberrantly overexpressed in multiple cancer types including head and neck squamous cell carcinoma, breast cancer, and prostate cancer, correlating with poor prognosis 2. In cancer contexts, RPS6KB2 promotes cell proliferation, invasion, and migration while inhibiting apoptosis 3. Mechanistically, RPS6KB2 can be transcriptionally activated by USF1 to drive B-cell non-Hodgkin lymphoma progression through the AKT/HDM2/p53 pathway 4. Additionally, RPS6KB2 upregulates proinflammatory cytokines, suggesting immunomodulatory functions relevant to tumor microenvironment interactions 3. Beyond cancer, RPS6KB2 shows relevance to inflammatory skin conditions and neurological function. Mendelian randomization analysis identified RPS6KB2 as a potential drug target in eczema and dermatitis pathogenesis 5, while genome-wide association studies suggest RPS6KB2 expression in the frontal cortex associates with word fluency cognitive measures 6. Genetic variation in RPS6KB2 also associates with colon cancer risk through interactions with related pathway genes 7.